@Article{dbt_mods_00056604,
  author = 	{Thiel, U.
		and Schober, S. J.
		and Ranft, A.
		and Gassmann, H.
		and Jabar, S.
		and Gall, K.
		and von L{\"u}ttichau, I.
		and Wawer, A.
		and Koscielniak, E.
		and Diaz, M. A.
		and Ussowicz, M.
		and Kazantsev, I.
		and Afanasyev, B.
		and Merker, M.
		and Klingebiel, T.
		and Prete, A.
		and Gruhn, B.
		and Bader, P.
		and J{\"u}rgens, H.
		and Dirksen, U.
		and Handgretinger, R.
		and Burdach, S.
		and Lang, P.},
  title = 	{No difference in survival after HLA mismatched versus HLA matched allogeneic stem cell transplantation in Ewing sarcoma patients with advanced disease},
  journal = 	{Bone Marrow Transplantation},
  year = 	{2021},
  month = 	{Jul},
  publisher = 	{Nature Publishing Group UK},
  address = 	{London},
  volume = 	{56},
  number = 	{7},
  pages = 	{1550--1557},
  keywords = 	{Bone metastases; Cancer immunotherapy},
  abstract = 	{Patients with advanced Ewing sarcoma (AES) carry a poor prognosis. Retrospectively, we analyzed 66 AES patients treated with allogeneic stem cell transplantation (allo-SCT) receiving HLA-mismatched (group A, n {\thinspace}={\thinspace}39) versus HLA-matched grafts (group B, n {\thinspace}={\thinspace}27). Median age at diagnosis was 13 years, and 15 years (range 3--49 years) at allo-SCT. The two groups did not differ statistically in distribution of gender, age, remission status/number of relapses at allo-SCT, or risk stratum. 9/39 (23{\%}) group A versus 2/27 (7{\%}) group B patients developed severe acute graft versus host disease (GvHD). Of patients alive at day 100, 7/34 (21{\%}) group A versus 9/19 (47{\%}) group B patients had developed chronic GvHD. In group A, 33/39 (85{\%}) versus 20/27 (74{\%}) group B patients died of disease and 1/39 (3{\%}) versus 1/27 (4{\%}) patients died of complications, respectively. Altogether 12/66 (18{\%}) patients survived in CR. Median EFS 24 months after allo-SCT was 20{\%} in both groups, median OS was 27{\%} (group A) versus 17{\%} (group B), respectively. There was no difference in EFS and OS in AES patients transplanted with HLA-mismatched versus HLA-matched graft in univariate and multivariate analyses. In this analysis, CR at allo-SCT is a condition for survival ( p {\thinspace}<{\thinspace}0.02).},
  note = 	{Zweitver{\"o}ffentlichung},
  issn = 	{0268-3369},
  doi = 	{10.1038/s41409-020-01200-x},
  url = 	{https://www.db-thueringen.de/receive/dbt_mods_00056604},
  url = 	{https://doi.org/10.1038/s41409-020-01200-x},
  file = 	{:https://www.db-thueringen.de/servlets/MCRFileNodeServlet/dbt_derivate_00059568/s41409-020-01200-x.pdf:PDF},
  language = 	{en}
}